18910 (2026). Hon Dr Ayesha Verrall to the Associate Minister of Health

18910 (2026). Hon Dr Ayesha Verrall to the Associate Minister of Health: Has pomalidomide been funded by Pharmac as a third-line treatment for relapsed or refractory multiple myeloma, if not, is it under consideration for funding?

Hon David Seymour: Yes, pomalidomide is funded by Pharmac as a second or later line treatment. I am advised by Pharmac it has been funded since 1 August 2024. I refer the Member to the following link for more information: https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-increase-access-to-lenalidomide-and-pomalidomide-through-a-brand-change-for-lenalidomide